OXFORD, UK, September 4th, 2015
PharmaVentures is pleased to announce that it acted as advisor to Douglas Pharmaceuticals, New Zealand's largest pharmaceutical manufacturer, in acquiring from Auckland-based Vital Foods their Phloe® product line in New Zealand for an undisclosed sum. The deal, completed on 1st September, includes an option for additional territories.
OXFORD, UK, June 30th, 2015
PharmaVentures is pleased to announce that it has acted as advisor to CM Technology Oy (CMT) on its divestment of certain assets to Yokogawa Electric Corporation (Yokogawa). The assets relate to CMT's world leading capabilities in cellular imaging and analysis.
This transaction is the latest in a series of successful global deals in the life science research tools sector for PharmaVentures' clients.
OXFORD, UK, May 29th, 2015 Pharma
PharmaVentures is pleased to announce that it has acted as advisor to one of the top US pharmaceutical companies in its divestment of one of its manufacturing facilities to a US contract manufacturer. The divestment, completed in mid-May, has led to the protection of hundreds of jobs.
This divestment follows PharmaVentures continued success in M&A including the executing of multiple divestments for several of the largest pharmaceutical companies in the world.
Oxford, UK. March 4th 2015
Following another year of successful deal making, PharmaVentures is pleased to announce the appointment of Graham Combe who has joined its Business Development team.
OXFORD, UK,February 10th, 2015
PharmaVentures is pleased to announce that it is to increase its life science presence in the North America by establishing a new base in Boston, MA, immediately.
OXFORD, UK, January 27th, 2015
PharmaVentures is pleased to announce that their client Novartis has entered into exclusive negotiations with the University of Brighton on the purchase of its UK Horsham site announced on the 26th January 2015.
Pharma licensing agreement OXFORD, UK, January 13th, 2015
PharmaVentures is pleased to announce that it has acted as advisor to ESTEVE in their successful pharma licensing agreement with MundiPharma Laboratories GmbH for E-58425, a first in class NSAID/Opioid API-API co-crystal for the treatment of pain.
Oxford, UK, January 12th 2015
PharmaVentures has become the latest Partner to join forces with One Nucleus. Both PharmaVentures and One Nucleus are committed to playing an active and supportive role in assisting in the success of the life sciences sector nationally and internationally.
OXFORD, UK, October 1st, 2014
PharmaVentures is pleased to announce that it has acted as advisor on deal terms to Plethora Solutions Holdings on their recently signed Licensing Agreement with Recordati to commercialise PSD502™, a novel treatment for premature ejaculation.
OXFORD, UK, September 24th, 2014
PharmaVentures are delighted to announce that Aki von Roy has joined as an Associate, based in Auckland, New Zealand. He has over 30 years experience in Big Pharma and 16 years in biotech. He has been involved in over 18 start-up or merger ventures as director or investor.